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Circadian clock mechanisms are far-from-equilibrium dissipative structures. Peroxisome
proliferator-activated receptors (PPAR alpha, beta/delta, and gamma) play a key role in
metabolic regulatory processes, particularly in heart muscle. Links between circadian
rhythms (CRs) and PPARs have been established. Mammalian CRs involve at least two
critical transcription factors, CLOCK and BMAL1 (Gekakis et al., 1998; Hogenesch et al.,
1998). PPAR gamma plays a major role in both glucose and lipid metabolisms and presents
circadian properties which coordinate the interplay between metabolism and CRs. PPAR
gamma is a major component of the vascular clock. Vascular PPAR gamma is a peripheral
regulator of cardiovascular rhythms controlling circadian variations in blood pressure and
heart rate through BMAL1. We focused our review on diseases with abnormalities of CRs
and with primary or secondary cardiac dysfunction. Moreover, these diseases presented
changes in the Wnt/beta-catenin pathway and PPARs, according to two opposed profiles.
Profile 1 was defined as follows: inactivation of the Wnt/beta-catenin pathway with
increased expression of PPAR gamma. Profile 2 was defined as follows: activation of the
Wnt/beta-catenin pathway with decreased expression of PPAR gamma. A typical profile
1 disease is arrhythmogenic right ventricular cardiomyopathy, a genetic cardiac disease
which presents mutations of the desmosomal proteins and is mainly characterized by fatty
acid accumulation in adult cardiomyocytes mainly in the right ventricle. The link between
PPAR gamma dysfunction and desmosomal genetic mutations occurs via inactivation
of the Wnt/beta-catenin pathway presenting oscillatory properties. A typical profile 2
disease is type 2 diabetes, with activation of the Wnt/beta-catenin pathway and decreased
expression of PPAR gamma. CRs abnormalities are present in numerous pathologies
such as cardiovascular diseases, sympathetic/parasympathetic dysfunction, hypertension,
diabetes, neurodegenerative diseases, cancer which are often closely inter-related.
Keywords: circadian rhythms, Wnt/beta-catenin, PPAR, diabetes, hypertension, myocardial ischemia,
neurodegenerative diseases, colon cancer
Abbreviations: CR, circadian rhythm; PPAR, Peroxisome proliferator-activated
receptor; SCN, suprachiasmatic nucleus; APC, adenomatous polyposis coli; Dsh,
Disheveled; GSK3-beta glycogen synthase kinase 3-beta; LRP5/6, low density
lipoprotein receptor-related protein 5/6; Fzd, Frizzled; Tcf/Lef, T cell/lymphoid-
enhancing binding; Clock, Circadian locomotor output cycles kaput; Ccm,
cardiomyocyte-specific clock mutant; FAO, fatty acid oxidation; RXR, retinoid X
receptor; PPRE, peroxisome proliferator response element; TZD, thiazolidinedione;
Bmal1, Brain andmuscle aryl-hydrocarbon receptor nuclear translocator-like; Cry,
cryptochrome; Per, Period; Ccg, clock-controlled genes; Ror, related orphan recep-
tor; TZD, thiazolidinediones; ARVC, arrhythmogenic right ventricular cardiomy-
opathy; DSG, desmoglein; DSC, desmocollin; PKP, plakophilin; PG, plakoglobin;
DSP, desmoplakin; PDK, pyruvate deshydrogenase kinase; HIF1 alpha, hypoxia-
inducible factor 1 alpha; PGC-1 alpha, PPAR gamma co-activator 1 alpha;M-CPT1,
muscle carnitine palmitoyltransferase 1; ANS, autonomous nervous system; AD,
Alzheimer Disease; HD, Huntington disease; ALS, Amyotrophic lateral sclerosis;
PD, Parkinson disease; MS, Multiple sclerosis; FRDA, Friedreich ataxia; Abeta,
amyloid-beta; FXN, Frataxin.
INTRODUCTION
CRs are biological temporal processes that display endogenous,
entrainable free-running periods that last approximately 24 h.
They are driven by molecular internal clocks which can be reset
by environmental light-dark cycles. Circadian clocks are tran-
scriptionally based molecular mechanisms which comprise feed-
back loops (Edery, 2000). The molecular basis of CRs have first
been clarified in Drosophila and Neurospora, then in cyanobac-
teria, plants, and mammals (Reppert and Weaver, 2002). All
living organisms adjust their physiology and behavior to the
24-h day-night cycle under the governance of circadian clocks.
Circadian clocks may provide a selective advantage of anticipa-
tion, thus allowing organisms to respond efficiently to various
stimuli at the appropriate time. In mammals, sleep-awake and
feeding patterns, hormone secretion, heart rate, blood pressure,
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energy metabolism, and body temperature exhibit CRs. Their
disruptionsmay have deleterious effects. People submitted to shift
working, frequent transmeridian air flight, exposure to artificial
light exhibit a particularly high incidence of metabolic syndrome
and obesity. CR dysfunctions in blood pressure and heart rate,
which are both partly regulated by PPAR gamma are involved in
arrhythmias which may lead to sudden cardiac death, myocardial
infarction or stroke, often occurring at the early morning dur-
ing the surge in blood pressure. CRs are dissipative structures
due to a negative feedback produced by a protein on the expres-
sion of its own gene (Goodwin, 1965; Hardin et al., 1990). They
operate far-from- equilibrium and generate order spontaneously
by exchanging energy with their external environment (Prigogine
et al., 1974; Goldbeter, 2002; Lecarpentier et al., 2010).
THE REGULATORY SITES OF CIRCADIAN RHYTHMS
The master regulator site of CRs is the suprachiasmatic nucleus
(SCN) inside the hypothalamus in which core clock genes are
rhythmically expressed (Weaver, 1998). In addition to this cen-
tral clock, each organ has its own biological clock system, termed
peripheral clock. The SCN and most peripheral tissues such
as heart, blood vessels, skeletal muscles, kidneys, liver, and fat,
govern numerous functions that are synchronized with the sleep-
awake cycle (Zylka et al., 1998). In the cardiovascular system,
circadian clocks have been described within numerous mam-
malian cells, such as cardiomyocytes, vascular smooth muscle
cells, endothelial cells, and fibroblasts (McNamara et al., 2001;
Nonaka et al., 2001; Durgan et al., 2005, 2007; Takeda et al., 2007).
Peripheral clocks have their own regulatory mechanisms, which
are specific to each peripheral organ by regulating the expression
of clock-controlled genes (Ccg). CRs have been demonstrated in
approximately 8–10% of total genes expressed in mouse heart
and liver, more than 90% of them depending on self-autonomous
local diurnal oscillators (Storch et al., 2002).
GENES AND PROTEINS
Important genes are involved in CRs including Clock (Circadian
locomotor output cycles kaput), Bmal1 (brain and muscle aryl-
hydrocarbon receptor nuclear translocator-like 1), Cry1 (cryp-
tochrome 1), Cry2 (cryptochrome 2), Per1 (Period 1), Per2
(Period 2), Per3 (Period 3), and Ccg. They organize transcrip-
tion/translation autoregulatory feedback loops comprising both
activating and inhibiting pathways (Reppert and Weaver, 2002;
Schibler and Sassone-Corsi, 2002). A complex network is formed
by all these genes which interlock feedback and forward sub-
tle loops whose complete time course is approximately 24 h.
Clock genes Per1, Per2, Bmal1, and Cry1 display rhythmic expres-
sion in human hearts (Leibetseder et al., 2009). At the start
of the day, transcription of Clock and Bmal1 begins. The pro-
teins CLOCK and BMAL1 are synthesized and then associate
as dimers which bind to regulatory DNA sequences (E-box ele-
ments) of the promoters of target genes. CLOCK: BMAL1 dimer
activates circadian gene transcription of Period genes (Per1, 2,
and 3), Chryptochrome genes (Cry 1 and 2), Rev-erb, Ror (related
orphan receptor), and Ccg, and drives their rhythmic expression
(Reppert and Weaver, 2001, 2002; Young and Kay, 2001; Canaple
et al., 2006; Chen and Yang, 2014). Into the cytoplasm, the PER
and CRY proteins dimerize and, after translocation to the nucleus,
modulate the transcriptional activity of CLOCK: BMAL1 (Kume
et al., 1999). Concentrations of BMAL1 and PER proteins cycle
in counterpoint. PER2 is a positive regulator of the Bmal1 loop.
Protein CRY is a negative regulator of both Per and Cry loops.
ROR alpha enhances Bmal1 transcription (Akashi and Takumi,
2005), while the nuclear receptor Rev-erb inhibits it (Ueda et al.,
2002). Rev-erb alpha binds to ROR-responsive element (RORE)
in the Bmal1 promoter and represses its transcriptional activ-
ity (Preitner et al., 2002). Rev-erb alpha protein is a member of
the nuclear receptor family of intracellular transcription factors.
The gene Rev-erb alpha is a major regulatory component of the
circadian clock (Yin et al., 2006) and among various properties,
is involved in the circadian expression of plasminogen activator
inhibitor type 1 (Wang et al., 2006).
CIRCADIAN RHYTHMS AND MUTATIONS OF GENES
Mutations or deletions of clock genes in mice have shown the key
role of circadian clocks to ensure the proper timing of metabolic
and cardiovascular processes. There is an increased pathologi-
cal remodeling and vascular injury together with an aberrant CR
in Bmal1-knockout and Clock mutant mice (Anea et al., 2009).
Aortas from Bmal1-knockout and Clock mutant mice exhibit
endothelial dysfunction. Akt (protein kinase B) and subsequent
nitric oxide signaling is significantly attenuated in arteries from
Bmal1-knockout mice. Bmal1 is a key regulator of myogene-
sis which may represent a temporal regulatory mechanism to
fine-tune myocyte differentiation (Chatterjee et al., 2013). Bmal1
regulates adipogenesis via the Wnt signaling pathway (Guo et al.,
2012). Disruption of Bmal1 in mice led to increased adipogen-
esis, adipocyte hypertrophy, and obesity. Attenuation of Bmal1
function resulted in down-regulation of genes in the canoni-
cal Wnt pathway known to suppress adipogenesis. Promoters of
these genes, i.e., beta-catenin, Disheveled (Dsh), T cell-enhancing
binding (Tcf) display Bmal1 occupancy, indicating direct circa-
dian regulation by Bmal1. Among several abnormalities, deletion
of the clock gene Bmal1 in mice adipose tissue induces obesity
(Paschos et al., 2012). The cardiomyocyte-specific clock mutant
(Ccm) is a mouse model wherein the cardiomyocyte circadian
clock is selectively suppressed (Young et al., 2001b,c; Durgan et al.,
2006). Ccm presents a temporal suspension of the cardiomyocyte
circadian clock at the wake-to-sleep transition (Young, 2009).
Numerous mutations of genes will be discussed in the following
paragraphs of this review.
CIRCADIAN RHYTHMS AND HEART PERFORMANCE
Loss of synchronization between the internal clock and external
stimuli can induce cardiovascular organ damage. Discrepancy in
the phases between the central and peripheral clocks also seems
to contribute to progression of cardiovascular disorders (Takeda
and Maemura, 2011). Peripheral clocks have their own roles spe-
cific to each peripheral organ by regulating the expression of Ccg,
although the oscillation mechanisms of the peripheral clock are
similar to that of the SCN (Takeda et al., 2007). Both the physi-
ological and pathological functions of cardiovascular organs are
closely related to CRs. Heart rate, blood pressure and endothelial
function show diurnal variations within a day. A profound pat-
tern exists in the time of day at which the deathmay occur (Takeda
and Maemura, 2011). The onset of cardiovascular disorders such
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as acute coronary syndrome, atrial arrhythmias, and subarach-
noid hemorrhage exhibits impairment of diurnal oscillations.
Stroke and heart attacks most frequently happen in the morning
when blood pressure surges.
Over the course of the day, the normal heart anticipates,
responds and adapts to physiological alterations within its envi-
ronment. Contractile performance, carbohydrate oxidation, fatty
acid oxidation (FAO), mitochondrial function, oxygen consump-
tion, and expression of all metabolic genes show diurnal vari-
ations. The circadian clock plays an important role in cardiac
homeostasis through the anticipation of daily workload. In wild-
type mice, the ejection fraction (EF) and the shortening fraction
(FS) show circadian variation (Wu et al., 2011). The diurnal
variations in EF and FS are altered in mice with disruptions
of circadian clock genes and are significantly diminished under
an imposed light regimen. The circadian variation in blood
pressure and heart rate is disrupted in Bmal1(-/-) and Clock
(mut) mice in which core clock genes are deleted or mutated
(Curtis et al., 2007). Bmal1 deletion abolishes the 24-h fre-
quency in cardiovascular rhythms. However, a shorter ultradian
rhythm remains. Sympathetic adrenal function is disrupted in
these mice.
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARs)
PPARs (alpha, beta/delta, and gamma) are nuclear receptors
belonging to the nuclear receptor superfamily. They function
as transcription factors within the cell nuclei and regulate the
expression of several target genes. PPARs play a pivotal role
in various physiological and pathological processes, especially
in energy metabolism, development, carcinogenesis, extracellu-
lar matrix remodeling, and CRs (Lockyer et al., 2009). PPARs
heterodimerize with the retinoid X receptor (RXR). PPARs are
activated by their respective ligands, either endogenous fatty acids
or pharmaceutical drugs which are potential therapeutic agents.
Numerous natural and synthetic compounds, i.e., fatty acids,
eicosanoids, arachidonic acid, hypolipidemic fibrates activating
PPAR alpha, and anti diabetic thiazolidinediones (TZD) acti-
vating PPAR gamma, serve as activators of PPARs. PPARs are
involved in numerous pathologies such as obesity, dyslipidemia,
insulin resistance, type 2 diabetes, hypertension, cardiac hyper-
trophy (Berger and Moller, 2002; Kelly, 2003). PPAR beta/delta
was not studied in this review.
PPARs AND CIRCADIAN RHYTHMS
PPARs integrate the mammalian clock and energy metabolism
(Chen and Yang, 2014). PPARs have been shown to be rhyth-
mically expressed in mammalian tissues (Yang et al., 2006) and
to directly interact with the core clock genes (Inoue et al., 2005).
PPAR beta/delta has not been studied in this review.
PPAR alpha
PPAR alpha presents CRs in several organs, i.e. heart, muscles,
liver, and kidney (Lemberger et al., 1996; Yang et al., 2006).
PPAR alpha expression is stimulated by stress, glucocorticoid
hormones, and insulin whose secretion follows CRs (Lemberger
et al., 1994). Importantly, PPAR alpha is a direct target of genes
(Bmal1 and Clock) through an E-box process (Oishi et al., 2005).
The circadian expression of PPAR alpha mRNA is abolished in
the liver of homozygous Clock mutant mice and is regulated by
the peripheral oscillators in a CLOCK-dependent mechanism. In
rodent liver, there is a regulatory feedback loop involving BMAL1
and PPAR alpha in peripheral clocks. This regulation occurs via
a direct binding of PPAR alpha on a PPAR alpha response ele-
ment located in the Bmal1 gene promoter. Moreover, BMAL1 is
an upstream regulator of PPAR alpha gene expression (Gervois
et al., 1999; Canaple et al., 2006). Several genes such as those
encoding for sterol regulatory element binding protein, HMG-
CoA reductase, fatty acid synthase, are involved in the lipid
metabolism. They display circadian fluctuations, and their activ-
ities are diminished or suppressed in PPAR alpha knockout mice
(Patel et al., 2001; Gibbons et al., 2002). PPAR alpha directly
regulates the transcriptional activity of Bmal1 and Rev-erb alpha
through the PPRE located in the promoter site of their respec-
tive genes. Per2 interacts with nuclear receptors including PPAR
alpha and Rev-Erb alpha and serves as a co-regulator of nuclear
receptor-mediated transcription. The PPAR alpha agonist fenofi-
brate increases transcription and resets circadian expression of
Bmal1, Per2, and Rev-erb alpha in mouse liver (Canaple et al.,
2006) and cultured hepatocytes (Gervois et al., 1999). Moreover,
bezafibrate can phase advance the rhythmic expression of Bmal1,
Per2, and Rev-erb alpha in several mouse peripheral tissues (Shirai
et al., 2007; Oishi et al., 2008).
PPAR gamma
PPAR gamma exhibits variations in diurnal expression in mouse
fat, liver, and blood vessels (Yang et al., 2006; Wang et al., 2008).
Deletion of PPAR gamma in mouse suppresses or diminishes
diurnal rhythms (Yang et al., 2012). CRs have been analyzed
in two strains of whole-body PPAR gamma null mouse mod-
els, i.e., Mox2-Cre mice (MoxCre/flox) or induced by tamoxifen
(EsrCre/flox/TM). Diurnal variations in blood pressure and heart
rate are blunted in MoxCre/flox mice. Impaired rhythmicity of
the canonical clock genes is observed in adipose tissue and liver.
This shows the important role of PPAR gamma in the coor-
dinated control of circadian clocks, metabolism, and cardiac
performance (Yang et al., 2012). Moreover, insulin resistance is
correlated with a non-dipper type—i.e., with no blood pressure
decrease during the circadian cycle- in essential hypertension.
TZD are oral hypoglycemic agents act as insulin sensitizers and
possess antihypertensive properties. TZD therapy with pioglita-
zone transforms the CR of blood pressure from a non-dipper
to a dipper type (Anan et al., 2007). PPAR gamma contributes
to maintain the diurnal variations of both blood pressure and
heart rate.
Rev-Erb alpha, an orphan nuclear receptor and a core clock
component, is expressed after PPAR gamma activation with
rosiglitazone in rat. Activated PPAR gamma induces Rev-Erb
alpha promoter activity by binding to the response element
Rev-DR2. Mutations of the 5′ or 3′ half-sites of the response
element suppress PPAR gamma binding and transcriptional acti-
vation (Fontaine et al., 2003). PGC-1 alpha, a transcriptional
co-activator that regulates energy metabolism, is rhythmically
expressed in the liver and skeletal muscle of mice. PGC-1 alpha
stimulates the expression of clock genes, notably Bmal1 and
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Rev-erb alpha, through co-activation of the ROR family of orphan
nuclear receptors. Mice lacking PGC-1 alpha show abnormal CRs
of activity, body temperature, and metabolic rate (Liu et al.,
2007a).Nocturnin, a circadian-regulated gene, promotes adipoge-
nesis by stimulating PPAR gamma nuclear translocation (Kawai
et al., 2010). Nocturnin binds to PPAR gamma and stimulates
its transcriptional activity whereas its deletion suppresses PPAR
gamma oscillations (Green et al., 2007). The hormone-dependent
interaction of the nuclear receptor RXR alpha with CLOCK neg-
atively regulates CLOCK: BMAL1-mediated transcriptional acti-
vation of clock gene expression in vascular cells. RXR alpha can
phase shift Per2mRNA rhythmicity, providing amolecular mech-
anism for hormonal control of clock gene expression (McNamara
et al., 2001).
CANONICAL Wnt/BETA-CATENIN PATHWAY
Beta-catenin plays a key role during epithelial-mesenchymal
transition (EMT), that characterizes normal embryonic devel-
opment, tissue regeneration and cancer proliferation (Heuberger
and Birchmeier, 2010). Beta-catenin is a normal constituent of
the zonula adherens, a major cell-to-cell adhesion complex in
pavement-like tissues. During EMT, the loss of cadherins disrupts
the zonula adherens, thus liberating beta-catenin into the cyto-
plasm. This molecule then migrates to the cell nucleus where it
activates the Wnt/beta-catenin target genes. A hallmark of the
canonical Wnt pathway activation is the elevation of cytoplasmic
beta-catenin protein levels, the subsequent nuclear translocation
and further activation of beta-catenin specific gene transcrip-
tion (Ben-Ze’ev and Geiger, 1998; Klymkowsky et al., 1999;
Zhurinsky et al., 2000; Moon et al., 2002; Maeda et al., 2004; Sen-
Chowdhry et al., 2005; Garcia-Gras et al., 2006), (Figure 1). In the
absence of Wnt ligands, beta-catenin is recruited into a destruc-
tion complex that contains adenomatous polyposis coli (APC)
and Axin, which facilitate the phosphorylation of beta-catenin
by glycogen synthase kinase 3- beta (GSK3-beta). GSK3-beta
phosphorylates the N-terminal domain of beta-catenin, thereby
targeting it for ubiquitination and proteasomal degradation. In
the presence of a Wnt ligand, the binding of Wnt to Frizzled
(Fzd) leads to activation of the phosphoprotein Disheveled (Dsh).
Dsh recruits Axin and the destruction complex to the plasma
membrane, where Axin directly binds to the cytoplasmic tail of
LRP5/6. Axin is degraded, which decreases beta-catenin degra-
dation. The activation of Dsh also leads to the inhibition of
GSK3-beta by phosphorylation, which further reduces the phos-
phorylation and degradation of beta-catenin. The beta-catenin
degradation complex is inactivated with recruitment of axin to
the plasma membrane, thus stabilizing the non-phosphorylated
beta-catenin which translocates to the nucleus. Beta-catenin
binds to T cell/lymphoid-enhancing binding (Tcf/Lef) tran-
scription factors. The resulting complex becomes active by
displacing Grouchos, leading to activation of numerous target
genes.
FIGURE 1 | The Wnt/beta-catenin pathway. (A) In the absence of
Wnt, cytosolic beta-catenin is phosphorylated by GSK3 beta. APS and
AXIN complex with GSK3 beta and beta-catenin to enhance the
destruction process into the proteasome. Phosphorylated beta-catenin is
recognized by the ubiquitin ligase beta -TrCP, ubiquinated and degraded.
The Wnt pathway is in an “off state.” (B) In the presence of Wnt,
Wnt binds both Frizzled and LRP5/6 receptors to initiate
GRK5/6-mediated LRP phosphorylation and disheveled-mediated Frizzled
internalization. Disheveled membrane translocation leads to dissociation
of the AXIN/APC/GSK3 beta complex. Beta-catenin phosphorylation is
inhibited and accumulates into the cytosol. Beta-catenin then
translocates to the nucleus to bind Lef-Tcf co-transcription factors,
which induces the Wnt-response gene transcription. Abbreviations: APC,
adenomatous polyposis coli; Dsh, Disheveled; GSK3 beta, glycogen
synthase kinase 3 beta; LRP5/6, low density lipoprotein receptor-related
protein 5/6; Fzd, Frizzled.
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CANONICAL Wnt/BETA-CATENIN PATHWAY AND PPAR GAMMA
Numerous studies have shown the direct interaction between
beta-catenin and PPAR gamma (Moldes et al., 2003; Jansson et al.,
2005; Garcia-Gras et al., 2006). PPAR gamma activation inhibits
the beta-catenin activation of Tcf/Lef transcription factors (Lu
and Carson, 2010). The TZD PPAR gamma agonists troglita-
zone, rosiglitazone, and pioglitazone, and the non-TZD PPAR
gamma activator GW1929 inhibit the beta-catenin-induced tran-
scription in a PPAR gamma dependent manner. Activation of
the Wnt-beta catenin pathway leads to osteogenesis, not adipo-
genesis and its inhibition leads to an increase in transcription of
PPAR gamma. Osteogenic pathway is linked to the stimulation
of Wnt signal leading to the final transcriptional activation of
early osteogenic markers such as RUNX-2 and ALP, mediated by
beta-catenin. Conversely, the adipogenic pathway involves inhi-
bition of Wnt pathway leading to ubiquitination/degradation of
beta-catenin which results in the transcription of PPAR gamma,
a pivotal initiator of adipogenesis. The canonical Wnt/beta-
catenin-PPAR gamma system determines themolecular switching
of osteablastogenesis vs. adipogenesis (Takada et al., 2009).
PPAR gamma is a prime inducer of adipogenesis that inhibits
osteoblastogenesis. Two different pathways switch the cell fate
decision from adipocytes to osteoblasts by suppressing the
transactivation function of PPAR gamma. TNF-alpha- and IL-
1-induced TAK1/TAB1/NIK signaling cascade attenuate PPAR
gamma-mediated adipogenesis by inhibiting the binding of PPAR
gamma to the DNA response element. PPAR gamma suppresses
Wnt/beta-catenin signaling during adipogenesis (Moldes et al.,
2003). Wnt/beta-catenin pathway operates to maintain the undif-
ferentiated state of preadipocytes by inhibiting adipogenic gene
expression. Importantly, there is a reciprocal relationship between
beta-catenin expression and PPAR gamma activity.
DISEASES ASSOCIATED WITH DEACTIVATION OF THE
Wnt/BETA-CATENIN PATHWAY AND INCREASED EXPRESSION OF
PPAR GAMMA
Numerous diseases present a common denominator: activation
of the Wnt/beta-catenin pathway decreased and the expression of
PPAR gamma increased. In most cases, expression of PPAR alpha
decreases.
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
ARVC is a rare human disease characterized by the development
of a fibro-fatty tissue in both ventricles, prominently involving the
right ventricular (RV)myocardium (Marcus et al., 1982; Fontaine
et al., 1999) (Figure 2). Cardiac dysfunction progressively devel-
ops, initially located at the RV and becoming biventricular in
about 20% of cases (Richardson et al., 1996; Hebert et al., 2004).
ARVC is most often an autosomic family-related disease. Genetic
mutations have been identified in about 50% of cases, occurring
among the five desmosomal proteins so far identified in the ven-
tricular cardiomyocyte, i.e., desmoglein 2 (DSG2), desmocollin
2 (DSC2), plakophilin 2 (PKP2), plakoglobin (PG), and desmo-
plakin (DSP) (Basso et al., 2009; Fressard et al., 2010). PPAR
abnormalities have been reported in ARVC with an increase in
PPAR gamma and a decrease in PPAR alpha in RV (Djouadi et al.,
2009).
Molecular mechanisms underlying ARVC are now better
understood. The link between PPAR gamma dysfunction and
desmosomal genetic mutations implicates the Wnt/beta-catenin
pathway. Thus, the suppression of canonical Wnt/beta-catenin
signaling by nuclear PG recapitulates the phenotype of ARVD
by exhibiting fat accumulation in cardiomyocytes, enhanced
myocyte apoptosis, ventricular dysfunction, and ventricular
arrhythmias in transgenic mice (Garcia-Gras et al., 2006). The
desmosomal PG also known as gamma-catenin, has structural
and functional similarities to beta-catenin, which is the effector
for canonical Wnt signaling (Moon et al., 2002). PG interacts
and competes with beta-catenin at multiple cellular levels with
a net negative effect on the canonical Wnt/beta-catenin signal-
ing pathway through Tcf/Lef transcription factors (Ben-Ze’ev
and Geiger, 1998; Klymkowsky et al., 1999; Zhurinsky et al.,
2000; Maeda et al., 2004). Mutating the desmosomal protein
DSP by impairing desmosome assembly set free gamma-catenin
from the desmosomes. As a consequence, gamma catenin translo-
cates to the nucleus and after competition with beta-catenin
suppresses signaling through the canonical Wnt/beta-catenin-
Tcf/Lef pathway. Suppression of DSP expression responsible for
human ARVC, leads to nuclear localization of PG and to sup-
pression of canonical Wnt/beta-catenin-Tcf/Lef1 signaling in cul-
tured atrial myocytes and in mouse hearts (Sen-Chowdhry et al.,
2005). Tcf/Lef1 suppression induces a transcriptional switch from
myogenesis to adipogenesis (Ross et al., 2000). This leads to
enhanced adipogenesis, fibrogenesis, andmyocyte apoptosis, thus
summarizing the phenotype of human ARVC (Corrado et al.,
1997).
Cardiac hypoxia
Hypoxia up-regulates expression of PPAR gamma
angiopoietin-related gene in cardiomyocytes (Belanger et al.,
2002). Hypoxia-inducible factor 1 alpha (HIF1 alpha) inhibits
PPAR alpha expression during hypoxia (Narravula and Colgan,
2001). Hypoxia leads to activation of HIF1 alpha (Krishnan et al.,
2009) and several genes involved in the regulation of glucose
transporters, glycolytic enzyme, and pyruvate deshydrogenase
kinase (PDK1). HIF1 alpha overexpression in vitro leads to
triacylglycerol accumulation, and reduced FAO due to inhibition
of PPAR alpha. Cardiac hypoxia represents a pathological state
where expression of PPAR alpha is reduced whereas that of
PPAR gamma is increased. Hypoxia triggers a cascade of cellular
metabolic responses including a decrease in mitochondrial
oxidative flux (Huss et al., 2001). Under hypoxic conditions,
myocytes exhibit significant accumulation of intracellular neutral
lipid consistent with reduced carnitine palmitoyltransferase-1
(CPT-1) activity and diminished FAO capacity. Hypoxia reduces
PPAR alpha/RXR binding activity and had no effect on the
nuclear level of PPAR alpha protein. Hypoxia reduced the nuclear
and cellular RXR levels and deactivates PPAR alpha by reducing
the availability of its obligate partner RXR. In rat models of
systemic hypoxia (Razeghi et al., 2001), cardiac hypoxia induces
a decrease in heart muscle transcript levels of PPAR alpha
and PPAR alpha-regulated genes (PDK4), muscle CPT-1, and
malonyl-CoA decarboxylase. This explains the increased reliance
of the heart for glucose during hypoxia.
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FIGURE 2 | Arrhythmogenic right ventricular cardiomyopathy (ARVC)
histology. (A) Typical morphology of right ventricular transmural free wall
section in a terminal ARVC heart transplant specimen, showing extensive
fibro-fatty replacement. A mid-mural residual muscular core (black
asterisk) is well-identified. Fibrosis is prominently located at the
subendocardium. Note the layer of normal subepicardial fat (Hematoxylin
Eosin Saffron staining, original magnification × 10). (B–D) are fresh tissue
snap frozen fragments representative of regions referred to as muscular
(B,C) and fatty myocardium, (D) respectively, stained with oil red O
(original magnification × 50).The red staining indicates neutral lipid
accumulation. (B) Note the normal discrete perinuclear staining of the
cardiomyocytes (white arrow) within the well-preserved myocardial core.
(C) In contrast, there is an abnormal major accumulation of fatty droplets
(not visible under standard staining) dispersed within the cells of the mid
mural muscular zone located above the residual muscular core and
surrounded by fatty tissue. Note the remaining normal central position of
the nucleus within the myocardial cells (red arrow). (D) Finally, there is a
direct transdifferentiation of myocardial cells into adipocytes within the
upper muscular zone bordering the normal subepicardial fat. Take notice
of the major confluence of the fatty droplets as well as of the final
aspect of total fatty transformation with migration of the nucleus beneath
the cell membrane (black arrows).
PPAR gamma co-activator 1 alpha (PGC-1 alpha) is a major
regulator of mitochondrial biogenesis and activity in the cardiac
muscle. Hypoxia stimulates the expression of PGC-1 alpha in car-
diac myocytes (Zhu et al., 2010). PGC-1 alpha stimulates the
expression of clock genes, particularly Bmal1 and Rev-erb alpha
(Liu et al., 2007a). Mice lacking PGC-1alpha present abnormal
diurnal rhythms of activity, body temperature, and metabolic
rate. Overexpression of PGC-1 alpha inhibits clock gene expres-
sion in both heart and skeletal muscles and decreases the expres-
sion of PPAR alpha. PGC-1 alpha overexpression abolishes the
diurnal variation of EF (Wu et al., 2011) and plays an important
role on cardiac function by regulating CRs of metabolic genes.
Ephrins belong to the family of receptor tyrosine kinases.
Interestingly, Ephrin-Eph cell signaling is linked to the Wnt/beta
catenin pathway (Clevers and Batlle, 2006) and favorably influ-
ences cardiomyocyte viability which ultimately preserves car-
diac function after myocardial infarction. Ephrin-Eph signaling
could potentially be a new therapeutic target in the treatment of
myocardial infarction (O’Neal et al., 2013). In non re-perfused
hearts of mice with a functional deletion of the CR gene mPer2,
myocardial infarct size is reduced. A decrease in infarct size in
mPer2-M mouse hearts following ischemia-reperfusion injury
and ischemic preconditioning is observed and improves preser-
vation of myocardial viability. In the mPer2-mutant mouse
myocardium cardio-protection occurs via the mechanisms con-
necting cardiac events, mitochondrial function, andmPer2 (Virag
et al., 2013).
Cardiac hypertrophy and cardiac overload
Development of cardiac hypertrophy and progression to heart
failure induce a change in myocardial metabolism, character-
ized by a switch from fatty acid utilization to glycolysis, and
lipid accumulation. PPAR gamma and HIF-1 alpha are key medi-
ators of lipid anabolism and glycolysis, respectively. They are
jointly up-regulated in hypertrophic cardiomyopathy and coop-
erate to mediate key changes in cardiac metabolism (Krishnan
et al., 2009). In response to pathological stress, HIF-1 alpha acti-
vates glycolytic genes, and PPAR gamma. This results in increased
glycolytic flux, glucose-to-lipid conversion via the glycerol-3-
phosphate pathway, and contractile dysfunction. Ventricular dele-
tion of HIF1 alpha in mice prevents hypertrophy-induced PPAR
gamma activation, the consequent metabolic re-programming,
and contractile dysfunction. HIF-1 alpha and PPAR gamma
protein expression is up-regulated in human and mouse cardiac
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hypertrophy. HIF 1 alpha directly activates PPAR gamma tran-
scription. PPAR gamma is a key downstream effector of HIF-
1 alpha-driven triacylglycerol accumulation in cardiomyocytes
(Krishnan et al., 2009).
In pathological hypertrophied heart, PPAR alpha expression
and activity are diminished, leading to a reduction in the capac-
ity for FAO and increased rate of glucose utilization (Barger et al.,
2000). Alpha 1-adrenergic agonist-induced hypertrophy of car-
diomyocytes in culture results in a switch in energy substrate
preference from fatty acids to glucose and in a significant decrease
in palmitate oxidation rates together with a reduction in the
expression of the gene encoding muscle carnitine palmitoyltrans-
ferase 1 (M-CPT1). Cardiac myocyte transfection has shown that
M-CPT1 promoter activity is repressed during cardiomyocyte
hypertrophic growth, an effect involving a PPAR alpha response
element. Hypertrophied myocytes exhibited reduced capacity
for cellular lipid homeostasis, as evidenced by intracellular fat
accumulation. Thus, during cardiomyocyte hypertrophic growth,
PPAR alpha is deactivated at several levels, leading to diminished
capacity for myocardial lipid metabolism. The functional conse-
quences of this metabolic switch from lipid to glucose may serve
to preserve ventricular function in the context of chronic pressure
overload (Young et al., 2001a). During cardiac pressure overload-
induced cardiac hypertrophy, the diurnal variation of metabolic
gene expression is completely suppressed and the cardiac perfor-
mance is impaired (Young et al., 2001b). The induction of clock
output genes is attenuated in the pressure-overloaded hypertro-
phied heart, providing evidence for a diminished ability of the
hypertrophied heart to anticipate and subsequently to adapt to
physiological alterations during the day (Young et al., 2001c).
Osteoporosis
The Wnt pathway induces differentiation of bone-forming cells
(osteoblasts) and suppresses the development of bone-resorbing
cells (osteoclasts). It is controlled by antagonists that interact
either with Wnt proteins (Wnts) or with Wnt co-receptors.
Wnts function as key regulators in osteogenic differentiation of
mesenchymal stem cells and bone formation. AberrantWnt path-
ways are associated with many osteogenic diseases (Rawadi and
Roman-Roman, 2005; Canalis, 2013). Both human genetics and
animal studies have pointed out the role of the Wnt/LRP5 path-
way as a major regulator of bone mass. In mice, down-regulation
or neutralization of Wnt antagonists enhances bone formation.
Mutations in LRP5 cause primary osteoporosis by reducing Wnt
signaling activity and result in decreased bone formation (Korvala
et al., 2012). Heterozygous PPAR gamma-deficient mice exhibit
high bonemass by stimulating osteoblastogenesis from bonemar-
row progenitors. Inhibition of PPAR gamma increases osteoblas-
togenesis and bone mass in male C57BL/6 Mice (Duque et al.,
2013). PPAR gamma inhibits osteoblast differentiation (Wan
et al., 2007).
Cardiovascular disease and osteoporosis are common
age-related conditions associated with significant morbidity and
mortality. An increasing body of biological and epidemiological
evidences provides support for a link between cardiovascular
disease and osteoporosis that cannot be explained by age
alone (Farhat and Cauley, 2008). Several hypotheses have
been proposed to explain the link between osteoporosis and
cardiovascular disease including shared risk factors, common
pathophysiological mechanisms and common genetic factors.
Alzheimer disease (AD)
AD is a progressive neurodegenerative disorder, neuropatho-
logically characterized by amyloid-beta (Abeta) plaques, and
hyperphosphorylated tau accumulation with hereditary missense
mutations in the amyloid precursor protein or presenilin-1 and
-2 (PSEN1 and PSEN2) genes. Presenilins are involved in modu-
lating beta-catenin stability; therefore familial AD-linked PSEN-
mediated effects can reduce the Wnt pathway (Boonen et al.,
2009). Tau phosphorylation is mediated by GSK-3 beta, a key
antagonist of the Wnt pathway. Sustained loss of function of
Wnt/beta-catenin signaling underlies the onset and progression
of AD (Inestrosa and Toledo, 2008; De Ferrari et al., 2014).
Downregulation of Wnt signaling induced by Abeta is associ-
ated with AD progression. Persistent activation of Wnt signaling
through Wnt ligands, or inhibition of negative regulators of Wnt
signaling, such as Dickkopf-1 and GSK-3 beta are able to pro-
tect against Abeta toxicity and ameliorate cognitive performance
in AD (Wan et al., 2014). A relationship between amyloid-beta-
peptide -induced neurotoxicity and a decrease in the cytoplas-
matic levels of beta-catenin has been observed. Although PPAR
gamma is elevated in the brain of AD individuals (Jiang et al.,
2008), activation of the Wnt signaling pathway may be proposed
as a therapeutic target for the treatment of AD.
In old mice engineered to lack Bmal1, there is evidence of
brain cell damage that looked similar to that seen in AD. BMAL1
in a complex with CLOCK regulates cerebral redox homeostasis
and connects impaired clock gene function to neurodegenera-
tion (Musiek et al., 2013). Altered CR synchronization has been
reported in the brain of AD patients (Cermakian et al., 2011).
CR disturbances affect as many as a quarter of AD patients.
Alterations in the SCN andmelatonin secretion are the major fac-
tors linked with CR abnormalities. Daytime agitation, night-time
insomnia, and restlessness are among the common behavioral
alterations observed in AD. Normally, in the interstitial fluid,
Abeta has a diurnal fluctuation with low levels during sleep and
peak levels during wake. Prolonged wake and/or orexin admin-
istration increase levels of the Abeta in the interstitial fluid of
the brain in mice. Orexin antagonist reduces amyloid deposits in
brain areas. There is a strong causal association between AD and
cardiovascular disease. Several cardiovascular risk factors includ-
ing hypertension and diabetes are also risk factors for dementia
(Stampfer, 2006).
Bipolar disorder and schizophrenia
The Wnt pathway and its key enzyme, GSK 3 beta, which
antagonizes the canonical Wnt pathway, play an important role
in regulating synaptic plasticity, cell survival, and CRs in the
mature central nervous system. This pathway is implicated in the
pathophysiology and treatment of bipolar disorder (Gould and
Manji, 2002; Valvezan and Klein, 2012). GSK3- beta-inhibitor
lithium chloride enhances activation of Wnt canonical signaling
(Hedgepeth et al., 1997; Sinha et al., 2005; Galli et al., 2013).
Lithium activates downstream components of the Wnt signaling
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pathway in vivo, leading to an increase of the beta-catenin pro-
tein. GSK3-beta phosphorylates and stabilizes the orphan nuclear
receptor Rev-erb alpha, a negative component of the circadian
clock. Lithium treatment of cells leads to rapid proteasomal
degradation of Rev-erb alpha and activation of clock gene Bmal1
(Yin et al., 2006). The origin of cyclicity in bipolar disorders has
been shown by means of a computational approach, and this dis-
ease enters the class of dissipative structures (Goldbeter, 2013).
Valproate, an effective medication for the prevention and treat-
ment of mood symptoms in bipolar disorder causes a decrease of
PPAR gamma signaling (Lan et al., 2008). Many cardiovascular
complications are seen in bipolar disorder (Swartz and Fagiolini,
2012).
An emerging role for Wnt and GSK-3 beta signaling pathways
has been found in schizophrenia (Singh, 2013). Sleep and circa-
dian rhythm disruption are seen in schizophrenia (Wulff et al.,
2012). Schizophrenia increases risks of cardiovascular disease,
particularly coronary heart disease, dyslipidemia, diabetes and
hypertension (Hennekens et al., 2005; Andreassen et al., 2013).
DISEASES ASSOCIATED WITH ACTIVATION OF THE
Wnt/BETA-CATENIN PATHWAY AND DECREASED EXPRESSION OF
PPAR GAMMA
Numerous diseases present a common denominator: the
Wnt/beta-catenin pathway is overexpressed and the PPAR gamma
expression is decreased. This explains why type 2 diabetes is
commonly associated with hypertension, sympathetic- parasym-
pathetic abnormalities, and cancers and why CR disruptions are
often observed among these pathologies. PPAR alpha expression
is often increased in these diseases.
Impaired sympathetic-parasympathetic system
PPAR gamma and sympathetic nerve activity (SNA) antagonis-
tically regulate energy metabolism and cardiovascular function
with the former promoting anabolism and vasorelaxation and the
later favoring catabolism and vasoconstriction (Yang et al., 2013).
Systemic inactivation of PPAR gamma can be generated consti-
tutively by using Mox2-Cre mice (MoxCre/flox) or inducibly by
using the tamoxifen system (EsrCre/flox/TM). There is an increase
in heart rate in both strains of null mice. PPAR gamma dele-
tion causes the activation of SNA. Rosuvastatin increases vascular
endothelial PPAR gamma expression and corrects blood pres-
sure variability in obese dyslipemic mice (Desjardins et al., 2008).
Sympathetic adrenal function is disrupted in both Bmal1(-/-)
and Clock (mut) mice (Curtis et al., 2007). Although a shorter
ultradian rhythm remains, Bmal1 deletion abolishes the 24-
h frequency in cardiovascular rhythms. In humans, heart rate
variability has been shown to be driven by an intrinsic mech-
anism (Hu et al., 2004; Ivanov et al., 2007). CRs and sleep
modulate the sympathetic-parasympathetic balance. Sleep depri-
vation induces a decrease in the global variability, and an
imbalance of the autonomous nervous system (ANS) with an
increase in sympathetic activity and a loss of parasympathetic
predominance. Human individuals homozygous for the longer
allele PER3(5/5) compared with PER3(4/4) subjects present an
elevated sympathetic predominance and a reduction of parasym-
pathetic activity (Viola et al., 2008). In mice, selective deletion
of the Bmal1 activator PPAR gamma in the vasculature induces
a diminution in heart rate circadian variations (Wang et al.,
2008). The CCM mouse model exhibits a decrease in heart rate.
Conversely, this model does not present differences in systolic,
diastolic, and mean blood pressures as compared with controls
(Bray et al., 2008).
Type 2 diabetes
PPAR alpha activity and its downstream targets are abnormally
activated in the diabetic heart, leading to a marked increase in
both fatty acid uptake and oxidation (Finck et al., 2005). Chronic
activation of the cardiac PPAR alpha pathway which occurs in the
diabetic heart, contributes to myocardial lipid accumulation and
diabetic cardiomyopathy (Finck et al., 2002). Diabetes alters the
circadian clock in the heart. The clock in the heart loses normal
synchronization with its environment during diabetes. Diabetes
and fasting activate the expression of cardiac FAO. Excessive fatty
acid import and oxidation may be a cause of pathological car-
diac remodeling in the diabetic heart (Finck and Kelly, 2002). In
type 2 diabetes, PPAR alpha is overexpressed and expression of
PPAR gamma is deceased. Some TZD PPAR agonists are used to
treat type 2 diabetes. The Wnt/beta-catenin signaling pathway is
involved in diabetes mellitus (Ip et al., 2012). Expression of PGC-
1 alpha is down-regulated in muscles of type 2 diabetic subjects
(Liang and Ward, 2006). PGC-1 alpha activates the expression
of insulin-sensitive GLUT4 in skeletal muscle and plays a role in
preventing insulin resistance and type 2 diabetes mellitus.
The mammalian clock (Bmal1, Clock, Cry1, Cry2, Per1, Per2,
and Per3) expresses CRs and the phases of these CRs are altered in
the hearts from streptozotocin-induced diabetic rats (Young et al.,
2002). Two BMAL1 haplotypes are associated with type 2 diabetes
and hypertension. This provides evidence of a causative role of
Bmal1 variants in pathological components of the metabolic syn-
drome (Woon et al., 2007). Rhythmic control of insulin release
is deregulated in humans with diabetes. Disruption of the clock
components Clock and Bmal1 leads to hypoinsulinemia and type
2 diabetes. Pancreatic islets express self-sustained circadian gene
and protein oscillations of the transcription factors CLOCK and
BMAL1. The phase of oscillation of the islet genes is delayed in
circadian mutant mice, and both Clock and Bmal1 mutants show
impaired glucose tolerance, reduced insulin secretion and defects
in size and proliferation of pancreatic islets (Marcheva et al.,
2010). In rodent models of type II diabetes, mean blood pressure
is mildly elevated. The elevation in blood pressure is accompanied
by changes in the circadian variation of blood pressure as demon-
strated in type 2 diabetes (db/db) mice. The daytime fall in blood
pressure in mice is significantly blunted in type 2 diabetes db/db
mice (Rudic and Fulton, 2009).
Hypertension
PPAR gamma in vascular muscle plays a role in the regula-
tion of vascular tone and blood pressure. Thus, mutations in
PPAR gamma induce severe hypertension and type 2 diabetes.
Transgenic mice with mutations in PPAR gamma in smooth mus-
cle present vascular dysfunction and severe systolic hypertension
(Halabi et al., 2008). PPAR gamma ligands lower blood pressure
in both animals and humans. PPAR gamma agonist rosiglitazone
Frontiers in Physiology | Integrative Physiology November 2014 | Volume 5 | Article 429 | 8
Lecarpentier et al. Circadian rhythms, Wnt/beta-catenin and PPAR
improves vascular function and lowers blood pressure in hyper-
tensive transgenic mice (Ryan et al., 2004). In mice, after vascular
PPAR gamma deletion, circadian variations of blood pressure
and heart rate are dampened through a dysregulation of Bmal1
(Wang et al., 2008). In a null mouse model with specific disrup-
tion of PPAR gamma in endothelial cells, PPAR gamma appears
to be an important regulator of blood pressure and heart rate
mimicking type 2 diabetes, and mediates the antihypertensive
effects of rosiglitazone (Nicol et al., 2005). PPAR gamma regulates
the renin-angiotensin system activity in the hypothalamic par-
aventricular nucleus and ameliorates peripheral manifestations
of heart failure (Yu et al., 2012). Activation of PPAR gamma
down-regulates the renin-angiotensin system. PPAR gamma is
expressed in key brain areas involved in cardiovascular and auto-
nomic regulation. Activation of central PPAR gamma reduces
sympathetic excitation and improves peripheral manifestations of
heart failure by inhibiting brain renin-angiotensin system activ-
ity. PPAR gamma ligands lower blood pressure in both animals
and humans, possibly via the PPAR gamma-mediated inhibition
of the angiotensin II type 1 receptor expression which results
in the suppression of the renin-angiotensin system (Sugawara
et al., 2010). Genetic variation in BMAL1 is associated with the
development of hypertension in man. BMAL1 dysfunction is
associated with susceptibility to hypertension and type 2 dia-
betes. In conditions of constant darkness, Cry1/Cry2 deficient
mice are hypertensive in the daytime (Rudic and Fulton, 2009).
Targeted deletion of Bmal1 in mice (Bmal1-KO) abolishes the CR
in blood pressure. Mice with targeted deletion of PPAR gamma in
the endothelium (EC-PPAR gamma-KO) exhibit a striking phe-
notypic resemblance to endothelial cell (EC)-specific deletion of
Bmal1 (EC-Bmal1-KO). The loss of PPAR gamma in the aorta of
both EC-PPAR gamma-KO mice leads to reduced expression of
Bmal1, Cry1, Cry2, and Per2. The ability of PPAR gamma to mod-
ulate blood pressure arises in part from its ability to transactivate
Bmal1.
Atherosclerosis
Wnt/beta-catenin signaling plays a key role in atherosclerosis
(Wang et al., 2002). Besides Wnt/beta-catenin, GSK3-beta acts as
a beta-catenin independent signal, and plays a crucial role in the
regulation of cell proliferation and vascular homeostasis. The pro-
gression of atherosclerosis is prevented by PPAR gamma ligands
in both animals and humans (Sugawara et al., 2010). Monocyte
adhesion to vascular endothelium is one of the early processes in
the development of atherosclerosis (Lee et al., 2006). Activation
of the canonical Wnt/beta-catenin pathway enhances monocyte
adhesion to endothelial cells.
Cardiac-restricted overexpression of PPAR alpha (MHC-PPAR)
In mice with cardiac-restricted overexpression of PPAR alpha
(MHC-PPAR), the expression of PPAR alpha target genes is
increased whereas that of genes involved in glucose transport and
utilization is repressed (Finck et al., 2002). The metabolic phe-
notype of MHC-PPAR mice mimics that of the diabetic heart.
MHC-PPAR hearts exhibits profiles of diabetic cardiomyopathy
including ventricular hypertrophy, activation of gene markers
of pathological hypertrophic growth, and systolic ventricular
dysfunction. Transgenic mice overexpressing PPAR alpha in mus-
cle (MCK-PPAR alpha mice) developed glucose intolerance.
Skeletal muscle ofMCK-PPAR alphamice exhibits increased FAO
rates and reduced insulin-stimulated glucose uptake. The effects
on muscle glucose uptake imply transcriptional repression of the
GLUT4 gene.
Aging
Aging is associated with various heart diseases, and this may be
attributable, in part, to the prolonged exposure of the heart to
cardiovascular risk factors. However, aging is also associated with
heart disorders such as diastolic dysfunction that are not nec-
essarily linked to the risk factors for cardiovascular diseases. A
mechanistic link between Wnt signaling and premature aging or
aging-related phenotypes has been demonstrated (Naito et al.,
2010). Tissues and organs from klotho-deficient animals show-
evidence of increased Wnt signaling. Both in vitro and in vivo,
continuousWnt exposure triggers accelerated cellular senescence.
Thus, klotho appears to be a Wnt antagonist (Brack et al., 2007;
Liu et al., 2007b). Specific mutations in the human gene encoding
lamin A cause premature aging. In mice and humans, these muta-
tions affect adult stem cells by interfering with the Wnt signaling
pathway (Meshorer and Gruenbaum, 2008). Overexpression of
Per in the fruit fly Drosophila melanogaster enhances long-term
memory, while in Per null flies memory is impaired. This sup-
ports a link for circadian genes in the processes of learning and
memory (Sakai et al., 2004). In aged animals, the normal pho-
tonic stimulation of Per1 expression is reduced. The free-running
period of Per1–luc rhythmicity is shortened in aged animals and
the amplitude of Clock and Bmal1 expression is decreased (Kolker
et al., 2003).
Neurodegenerative diseases
The common denominator overexpression of the Wnt/beta-
catenin pathway and the consequent decrease in PPAR gamma
expression play a central role in numerous neurodegenerative dis-
eases (Clevers, 2006a; MacDonald et al., 2009; Yang, 2012). PPAR
gamma agonists could potentially inhibit neuro-inflammation
and subsequently neurodegeneration. This may partially occur
through the ability of PPAR: RXR heterodimers to antago-
nize NFκB mediated gene transcription of several inflammatory
mediators such as COX-2, iNOS, and various proinflammatory
cytokines. It is not surprising that abnormalities of the car-
diovascular system and CRs dysfunction are often associated
with neurodegenerative pathologies. Sleep disturbances may pre-
dict manifestation of neurodegenerative diseases (Postuma and
Montplaisir, 2009).
Huntington disease (HD)
HD is a dominantly inherited cytosine-adenine-guanine (CAG)
repeat disorder with expanded polyglutamine (polyQ) tracts in
huntingtin, causing striatal and cortical degeneration (Walker,
2007). Huntingtin interacts with beta-catenin, beta -TrCP, and
axin. Normal huntingtin acts as a scaffold protein, promoting the
beta-catenin degradation by facilitating the recognition of beta-
catenin by beta -TrCP within the destruction complex (Godin
et al., 2010). The binding of beta-catenin to the destruction
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complex is altered in HD. The presence of an abnormal polyQ
expansion in mutant huntingtin leads to a decreased binding
to beta-catenin therefore impairing the binding of beta-catenin
to the destruction complex and subsequently resulting in beta-
catenin accumulation into the cytosol. Thus, beta-catenin levels
are up-regulated in HD. Mutant huntingtin alters the stability
and levels of beta-catenin. Reducing the canonical Wnt signal-
ing pathway confers protection against mutant huntingtin tox-
icity in Drosophila (Dupont et al., 2012). Knockdown of Wnt
ligands improves the survival of HD flies. Overexpression of
armadillo/beta-catenin destruction complex component (AXIN,
APC2, or GSK3-beta) increases the lifespan of HD flies.
Early-onset of cardiovascular disease is the second leading
cause of death in HD patients. Due to the ubiquitous expres-
sion of huntingtin, all cell types with high energetic levels can
be impaired. Expression of mutant huntingtin induces cardiac
dysfunction in the transgenic model of HD (line R6/2). R6/2
mice develop cardiac dysfunction with cardiac remodeling (e.g.
hypertrophy, fibrosis, apoptosis, beta1 adrenergic receptor down-
regulation) (Mihm et al., 2007). R6/1 transgenic mice exhibit
profound autonomic nervous system-cardiac dysfunction involv-
ing both sympathetic and parasympathetic systems, leading to
cardiac arrhythmias, and sudden death (Kiriazis et al., 2012).
A baroreceptor reflex dysfunction has been described in the
BACHD mouse model of HD (Schroeder et al., 2011). Several
studies report dysfunction of the autonomic nervous system in
HD patients. This may contribute to the increased incidence
of cardiovascular events in this patient population that often
leads to death. There is a blunted response of the barorecep-
tor reflex as well as a significantly higher daytime blood pres-
sure in BACHD mice compared to WT controls, which are
both indications of autonomic dysfunction. In humans, auto-
nomic dysfunction is present even in the middle stages of HD
and affects both the sympathetic and parasympathetic systems
(Andrich et al., 2002). Sleep and wake regions of the brain includ-
ing the brainstem, thalamus, hypothalamus, and cortex are also
affected in HD (Kremer et al., 1991). The SCN pacemaker is
functional in HD mouse models, so a dysfunction of the cir-
cadian circuitry has been proposed to contribute to circadian
abnormalities (Pallier and Morton, 2009). Central and periph-
eral clock gene expression is altered (Maywood et al., 2010). The
sleep/wake cycle is disrupted in HD patients characterized by
sleep fragmentation at night and delayed sleep phase (Aziz et al.,
2010).
Amyotrophic lateral sclerosis (ALS)
ALS is a neurodegenerative disease resulting in the progressive
loss of upper and lower limb motoneurons and leading to grad-
ual muscle weakening ultimately causing paralysis and death. The
Wnt/beta-catenin pathway plays a role in the neurodegeneration
of motor neurons in an in vitromodel of ALS (Pinto et al., 2013).
In ALS, a potentially therapeutic pathway may be the activa-
tion by PPAR gamma agonists due to their ability to block the
neuropathological damage caused by inflammation (Kiaei, 2008).
The neuroprotective effect of pioglitazone has been demonstrated
in G93A SOD1 transgenic mouse model of ALS and shows
a significant increase in their survival. In ALS, PPAR gamma
controls natural protective mechanisms against lipid peroxidation
(Benedusi et al., 2012).
Ataxin-2 gene (ATX2) is linked to a number of neurodegener-
ative disorders in humans including ALS and Parkinson disease
(PD). ATX2 protein inhibits the production of certain proteins
and plays a crucial role in the control of the circadian sleep/wake
cycle. ATX2 regulates the expression of the circadian protein Per
in Drosophila. By reducing expression of ATX2 in Drosophila,
the flies are active two and half hours longer. Patients suffer-
ing from a form of the neurodegenerative disease spinocerebellar
ataxia caused by ATX2mutations also experience rapid eye move-
ment sleep disruptions. ATX2 is necessary for PER accumulation
in circadian pacemaker neurons and thus determines period
length of circadian behavior. ATX2 is required for the function
of TWENTY-FOUR, an activator of PER translation. In humans
with ALS, CR of cortisol is impaired (Patacchioli et al., 2003).
Both sympathetic and parasympathetic dysfunctions are observed
in ALS (Druschky et al., 1999). There are sleep-wake disturbances
in patients with ALS (Lo Coco et al., 2011). In human ALS, heart
failure is a frequent common cause of death (Gdynia et al., 2006).
Parkinson disease (PD)
In a mouse model of PD, a cross talk between inflammatory
and Wnt/beta-catenin signaling pathways is involved (L’Episcopo
et al., 2012). The Wnt1 regulated Frizzled-1/beta-catenin signal-
ing pathway controls the mesencephalic dopaminergic neuron-
astrocyte crosstalk (L’Episcopo et al., 2011). The PPAR gamma
agonist pioglitazone modulates inflammation and induces neu-
roprotection in PD monkeys (Swanson et al., 2011) and mice
(Schintu et al., 2009). Expanded glutamine repeats of the ATX2
protein have been identified in fronto-temporal lobar degenera-
tion in PD (Ross et al., 2011). Moreover, a peripheral molecular
clock, as reflected in the dampened expression of the clock gene
Bmal1 in leukocytes is altered in PD patients (Cai et al., 2010).
There is a disappearance of CRs in a PD dogmodel (Hineno et al.,
1992). Sleep disturbances in PD may be related to CR dysfunc-
tion (Hack et al., 2014). Sleep complaints are present in almost
half of PD patients. PD patients exhibit increased sleep latency
and reduced sleep efficiency. In PD, there is a sustained eleva-
tion of serum cortisol levels, reduced circulating melatonin levels,
and altered Bmal1 expression (Breen et al., 2014). PD causes dys-
function of the diurnal autonomic cardiovascular regulation. This
dysfunction is profound in patients with severe PD (Haapaniemi
et al., 2001).
Multiple sclerosis (MS)
Wnt signaling is involved in the MS pathogenesis (Yuan et al.,
2012). Mice with experimental autoimmune encephalomyeli-
tis (EAE) have been widely used as a MS model with central
nervous system demyelination, neuro-inflammation, and motor
impairments. Wnt3a, a Wnt ligand for the canonical pathway,
is significantly increased in the spinal cord dorsal horn (SCDH)
of the EAE mice. Beta-catenin is also significantly up-regulated.
Wnt signaling pathways are up-regulated in the SCDH of the
EAE mice and aberrant activation of Wnt signaling contributes
to the development of EAE-related chronic pain. PPAR gamma
agonists modulate the development of experimental EAE (Drew
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et al., 2008). Moreover, the risk of myocardial infarction, stroke,
heart failure, and atrial fibrillation or flutter is increased in MS
patients (Jadidi et al., 2013).
Friedreich ataxia (FRDA)
FRDA is a debilitating, life-shortening, degenerative neuromus-
cular disorder, due to frataxin (FXN) deficiency. FRDA is charac-
terized by neuronal degeneration and heart failure, which are due
to loss of transcription of the FXN gene caused by a trinucleotide
repeat expansion. FXN is a mitochondrial protein involved in
iron–sulfur-cluster biogenesis, serving to bind and transfer iron
to key electron transport complexes and cytochrome C. Diabetes
mellitus and serious heart dysfunction (hypertrophic cardiomy-
opathy) are associated in most cases. The PPAR gamma agonist
Azelaoyl PAF increases FXN protein and mRNA expression in
human neuroblastoma cells SKNBE and in primary fibroblasts
from skin biopsies from FRDA patients. This offers new impli-
cations for the FRDA therapy (Marmolino et al., 2009). It has
been shown a coordinate dysregulation of the PPAR gamma co-
activator PGC-1 alpha and transcription factor Srebp1 in cellular
and animal models of FXN deficiency, and in cells from FRDA
patients. A genetic modulation of the PPAR gamma pathway
affects FXN levels in vitro, supporting PPAR gamma as a new
therapeutic target in FRDA (Coppola et al., 2009).
Colon cancer
Activation of beta-catenin-Tcf signaling has been observed in
colon cancer (Morin et al., 1997). Activation of the Wnt signal-
ing pathway via mutation of the APC gene is a critical event in the
development of colon cancer (Najdi et al., 2011). Inherited muta-
tions in APC lead to the development of non-invasive colonic
adenomas (polyps). Wnt pathway activation is a driving force
in the development of adenomas. Activation of the Wnt/beta-
catenin signaling pathway decreases PPAR gamma activity in
colon cancer cells (Jansson et al., 2005) and a loss-of-function
mutations in PPAR gamma is associated with human colon cancer
(Sarraf et al., 1999).
Colorectal cancer is linked to CR dysregulation (Savvidis
and Koutsilieris, 2012). Down-regulation of Per2 increases beta-
catenin protein levels and its target cyclin D, leading to cell
proliferation in colon cancer cell lines and colonic polyp forma-
tion. Per2 gene activation suppresses tumorigenesis in colon by
down-regulation of beta-catenin. Increased beta-catenin affects
the circadian clock and enhances PER2 protein degradation in
colon cancer. Suppression of human beta-catenin expression
inhibits cellular proliferation in intestinal adenomas. Disruption
of the peripheral intestinal CRs may contribute to intestinal
epithelial neoplastic transformation of human colorectal cancer.
The circadian expression of dihydropyrimidine dehydrogenase,
an enzyme that is implicated in the metabolism of the anti-
cancer drug 5-fluorouracil, may be regulated by Per1 in high-
grade colon tumors. The ephrin-Eph cell pathway is linked to
the Wnt/beta catenin pathway and is involved in colon cancer
(Clevers, 2006a,b).
Functional bowel disorders are associated with autonomic
disturbance (Tougas, 2000). People with type 2 diabetes have
an increased risk of developing colorectal cancer. Diabetes is
associated with a higher risk of colon cancer (Yuhara et al., 2011).
Heart disease increases at twice the risk of bowel cancer. Colon
cancer and coronary artery disease are known to share similar
risk factors (smoking, high-fat diet, obesity, diabetes, high blood
pressure, and sedentary lifestyle) which increase the risk of colon
cancer. This suggests that the two diseases may be connected
(Chan et al., 2007). People with coronary artery disease are more
likely to develop colon cancer than those without.
SYNTHESIS
Circadian rhythms (CRs) are particularly fascinating phenomena.
They go very far back in evolution. The existence of a CR is the
signature of instability. Beyond a point of bifurcation, an unstable
thermodynamic system can evolve spontaneously into a periodic
state. These periodic oscillations correspond to a phenomenon
of self-organization in time and have been called “dissipative
structures” (Prigogine et al., 1974). Dissipative structures are far-
from-equilibrium systems, such as cyclones, hurricanes, lasers,
Bénard cells, Belousov–Zhabotinsky reactions, Turing structures,
circadian rhythms, and more generally most of the living organ-
isms. CRs are based on the existence of negative feedback loops.
Oscillatory behavior gradually has been integrated into the living
world to become one of its major characteristics. In the cardio-
vascular system, circadian genes show properties of anticipation
and this makes it possible to coordinate lipid and carbohy-
drate metabolism with the cardiovascular function, especially
for blood pressure and heart rate. Dysfunction of CRs can be
associated with serious clinical problems and may induce a neg-
ative impact on quality of life, sometimes with a poor prognosis.
Abnormalities of circadian gene function may result in the occur-
rence of metabolic syndrome, obesity, and even more seriously,
stroke, or myocardial infarction.
Two major systems interfere with circadian genes, namely the
canonical Wnt pathway, and the PPAR system. In some cases of
diseases presenting profiles 1 or 2, there is not always evidence of
the exact influence of CRs on theWnt-beta catenin-PPAR gamma
pathway and cardiac function.PPAR gamma controls the circa-
dian Clock-Bmal1 genes in the vascular system. Importantly, there
is an opposite between activation of the Wnt pathway and PPAR
gamma. This is attested by their respective profiles in numer-
ous diseases, either cardiovascular diseases or pathologies with
cardiovascular complications. There is a subtle thermodynamic
regulation of CRs that run far-from-equilibrium; moreover, there
is the need to maintain the balance between the two systems
canonical Wnt and PPAR gamma. Indeed, activation of the Wnt
system with inactivation of PPAR gamma favors diabetes, hyper-
tension, several cancers, and neurodegenerative diseases. The
reverse is observed in ARVD, osteoporosis, Alzheimer disease,
bipolar disorder, schizophrenia, and myocardial ischemia. The
extreme complexity of the Wnt-PPAR systems and their numer-
ous inter-related pathways partly explain their involvement in
numerous diseases. We remain surprised by both the number and
the importance of these diseases, causing considerable morbidity,
and mortality and heavy social and economic costs.
The discovery and use of new agonist or antagonist pharma-
cological agents acting on PPARs, and more generally, directly or
indirectly implied in the canonical Wnt system, are particularly
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important. This leads to numerous novel therapeutic approaches.
PPAR gamma is a key regulator of lipid metabolism and its activa-
tion by some TZD is used for the treatment of type 2 diabetes and
protects against atherosclerosis. However, some TZD have been
reported to cause a higher rate of fractures in human patients.
Pharmacological inhibition of PPAR gamma represents a poten-
tial therapeutic approach for age-related bone loss. Induction of
theWnt pathway or inhibition ofWnt antagonists may offer ther-
apeutic opportunities in treating bone disorders, including osteo-
porosis. Antibodies targeting the Wnt inhibitor sclerostin lead
to increased bone mineral density in post-menopausal women.
Lithium, often used to treat bipolar disorder, blocks a Wnt antag-
onist, decreasing the patient’s risk of fractures. Lithium exerts
effects on components of the Wnt signaling pathway. The Wnt
signaling pathway plays an important role in the treatment of
bipolar disorder. The future development of selective GSK3- beta
inhibitorsmay have considerable utility not only for the treatment
of bipolar disorder but also for a variety of neurodegenerative dis-
orders. Therapies targeting theWnt pathway are not without risk,
and may lead to over-activation of Wnt/catenin and its associa-
tion with many tumors. However, it is conceivable that targeting
Wnt inhibitors may predispose the individuals to tumorigenic
phenotypes.
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